Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Phase II

Thumbnail
April 12, 2021

Sage’s technical tremor win fails to move

Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.

Thumbnail
April 07, 2021

Second-quarter catalysts for the smaller players

Key catalysts approach for Orphazyme, Gemini and Immutep.

Article image
Vantage logo
March 30, 2021

Wave waves goodbye to its first generation

The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.

Article image
Vantage logo
March 26, 2021

Proqr hopes to usherin a new ophthalmic therapy

The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.

Article image
Vantage logo
March 25, 2021

Biotech’s important clinical data readouts

The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.

Article image
Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

As Biogen heads towards important depression data, Sanofi looks to oncology for growth.

Article image
Vantage logo
March 24, 2021

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

Article image
Vantage logo
March 24, 2021

Cognito’s Alzheimer’s brainwave

Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.

Article image
Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.

Article image
Vantage logo
March 23, 2021

The Huntington’s pipeline takes a blow

The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.

Article image
Vantage logo
March 19, 2021

Wave gets another shot at Huntington’s

The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.